

Infosys

19 April 2024

RESULT UPDATE

Sector: IT & ITES	Rating: BUY
CMP: Rs 1,419	Target Price: Rs 1,660

Stock Info

Sensex/Nifty	72,489/21,996
Bloomberg	INFY IN
Equity shares (mn)	4142
52-wk High/Low	1733 / 1185
Face value	Rs 5
M-Cap	Rs 5878.5bn/USD 70.8bn
3-m Avg turnover	USD 123.6mn


Financial Snapshot (Rs mn)

Y/E Mar	FY24	FY25E	FY26E
Net sales	15,36,710	15,99,112	17,27,418
EBIT	3,17,470	3,25,428	3,54,108
EBIT (%)	20.7%	20.4%	20.5%
PAT	2,62,330	2,52,543	2,75,161
EPS	63.3	61.0	66.4
P/E (x)	22.4	23.3	21.4
P/B (x)	6.7	6.3	5.8
EV/EBITDA (x)	15.4	14.9	13.7
RoE (%)	29.8%	27.0%	27.2%
RoCE (%)	38.0%	35.0%	35.5%

Shareholding Pattern (%)

	Dec'23	Sep'23	Jun'23
Promoter	14.8	14.9	14.9
- Pledged	-	-	-
FII	33.7	33.6	33.4
DII	35.7	35.4	34.8
Others	15.8	16.1	16.8

Stock Performance (1-year)



Sameer Pardikar
sameerpardikar@systematixgroup.in
+91 22 6704 8041

Devanshi Kamdar
devanshikamdar@systematixgroup.in
+91 22 6704 8098

One-off impacts 4Q; FY25 revenue guidance conservative

Infosys (INFY) posted weak 4Q numbers on one-off impact on re-negotiation of a contract. Adjusting for the same, FY24 revenue grew at the lower end of the guided range. Management's revenue guidance for FY25 seems conservative and reflects i) no change to discretionary spending outlook for FY25, which continues to be weak at 3Q and 4Q FY24 levels, ii) seasonal weakness in 2HFY25, similar to FY24, and iii) lower manufacturing growth in FY25. Management has given conservative margin guidance for FY25 (keeping it at a similar level of FY24) despite all levers (higher utilization, rationalization of subcon, etc.) intact. We estimate this could be to accommodate the impact of likely re-negotiations in some of the other contracts. We have cut our revenue estimate to factor in the lower growth in FY25 and estimate 4.5% USD CAGR over FY23-26E. We estimate margins in the lower half of the guided range (earlier estimated at the upper half) to accommodate any one-time impact that could arise. We maintain BUY with a revised target price of Rs 1,660 (from Rs 2,000 earlier), based on 25x FY26E EPS (reduced from 26x to factor in the widened margin differential vs benchmark TCS). Key risks to our assumptions: 1) Abrupt exit/s from the leadership team, 2) sustained pressure on client discretionary spending in FY26, 3) continued re-negotiation of contracts impacting revenue and margins.

Weak FY24; recovery likely in FY25

For 4Q, the company reported flat YoY growth in CC, 0.2% in USD and 1.3% in INR terms. Europe and Rest of World (RoW) markets drove the growth, while North America and India markets remained weak during the quarter. Manufacturing, life sciences, energy & utilities, technology, and communication verticals drove growth, while BFSI and retail stayed weak during 4Q. INFY recorded large deal value (TCV – total contract value) of USD 4.5bn in 4Q, which comprised 30 deals, 44% of which were net new deals, including the 2 mega deals. This provides revenue visibility for FY25 and contains many short-term deals to be executed over the next 1 year. Management has provided 1% to 3% revenue growth guidance in CC for FY25.

Decline in operating margins

EBIT margin declined 40 bps QoQ to 20.1% due to 100 bps headwind from one-time impact of contracts, renegotiations, and re-scoping, and 80 bps headwind from additional impact on salary increases, higher brand building, and visa expenses, partially offset by 140 bps tailwinds comprising 60 bps from lower provision towards client receivables, 40 bps from project maximus, and 40 bps relating to reversal of 3Q impact from cyber incident (USD30mn impact in Q3 vs USD7-8mn impact in Q4).

Valuation & Outlook

At 23x 1-year forward multiple, INFY trades at a 15%+ premium to its last 10-year average multiple. On a relative basis, we value INFY at 25x FY26E EPS (15% discount to TCS target multiple) to arrive at a target price of Rs 1,660 per share. The discount reflects its relatively lower-margin profile to TCS. INFY's target multiple reflects i) the company's strong market positioning, ii) its status as key beneficiary of vendor consolidation, iii) its lower-margin profile to TCS, but better than HCLT (HOLD), WPRO (HOLD), TECHM (SELL), and iii) its healthy shareholder payout, etc.

What do the 4QFY24 result numbers say?

- INFY's 4QFY24 revenue growth is as follows: a) down 2.2% QoQ and flat YoY in CC terms, b) down 2.1% QoQ and up 0.2% YoY at USD 4,564mn in dollar terms, and c) down 2.3% QoQ and up 1.3% YoY at Rs 3,79,230mn in rupee terms.
- In USD revenue terms, North America and India showed a decline of 2.1% and 15.2% YoY, respectively. The two businesses make up for over 60% of INFY's revenue mix, whereas Europe grew at 6.2% YoY. Communication, energy & utilities, manufacturing, hi-tech and life sciences verticals (over 50% of revenue mix) reported YoY growth of 4.5%, 4.1%, 9.1%, 9% and 1.6%, respectively, while the BFSI and retail verticals witnessed 8.4% and 3.2% YoY decline, respectively.
- EBIT margin declined 40 bps QoQ to 20.1%, impacted by 100 bps headwind from one-time impact of contracts, renegotiation, and re-scoping, and 80 bps headwind from additional impact on salary increases, higher brand building, and visa expenses, partially offset by 140 bps tailwinds, comprising of 60 bps from lower provision for client receivables, 40 bps from project maximus, and 40 bps relating to 3Q impact from the cyber incident.
- For FY24, INFY reported revenue growth of a) 1.4% in CC terms, b) up 1.9% in dollar terms at USD 18,562mn, and c) up 4.7% in rupee terms at Rs. 15,36,710mn. The company reported EBIT margin of 20.7% in FY24, down 40 bps YoY. INFY declared a final dividend of Rs 20 per share along with a special dividend of Rs 8 per share in 4Q, taking its total dividend payout for FY24 to Rs 36 per share.
- INFY's robust large deal TCV of USD 4.5bn was up by 41% QoQ from a total 30 deals, of which 44% were net new deals and include 2 mega deals. The 30 deals are split up as follows: 8 from communication, 6 each from BFSI and retail, 4 each from manufacturing and life sciences and 2 from energy & utilities. Geography-wise, 16 were from North America, 10 from Europe, and 4 from RoW. For FY24, the company recorded a large deal TCV of USD 17.7bn, up by 80% YoY with a total of 90 deals.
- During the quarter, its attrition declined 30 bps QoQ to 12.6% during LTM. Currently, the company has an employee strength of 3,17,240.

Earnings call highlights

- Management expects to record slower growth in the US market in FY25 but is hopeful of Europe driving growth. The company expects fluctuations in the behaviors of industries in the US markets. For instance, it believes high interest rate capital-intensive industries like hi-tech and telecom may see weakness, but has a superior outlook on BFSI for FY25 vs FY24. The company however ruled out shifting focus to the Europe market vs US, citing both markets would remain strategic markets for them. The company did mention that they have strong presence in Nordic countries and expects their strong client relationships in the Europe market to drive growth.
- The company announced the acquisition of **In-tech holding** for EUR 450mn (EUR 170mn revenue in CY23), a leading engineering R&D (ER&D) services provider focused on the German automotive industry. The company mentioned that ER&D, especially within the automobiles vertical, has a strong runaway ahead, as car manufacturing companies are re-looking at the way cars are being manufactured. There has been an increased traction in areas like engineering, IoT (Internet of Things), supply chain, smart manufacturing, and digital


transformation. The company already has strong presence in ER&D (with a good margin profile), and it expects this acquisition to strengthen its position, as the addressable market for ER&D is large. The company's revenue and margin guidance for FY25 does not factor in any impact of the acquisition, according to management.

- The company mentioned that its FY25 revenue guidance reflects i) no change to FY25 discretionary spending outlook, which remains weak, as seen during 3Q and 4QFY24 ii) seasonal weakness in 2HFY25, which it believes would be like FY24, and iii) Slower manufacturing growth in FY25 vs FY24. The company does not expect re-negotiations in other mega deals as of now, which, during 4Q saw a 100bps impact on revenues and margins. The company did mention that 85% of the scope remains the same for this contract. INFY has higher exposure to discretionary work in its BFSI portfolio, which is impacting the company's growth in FY24. In addition, it also has exposure to mortgages, which have stayed soft in this environment, however management sees recovery on these subsegments in FY25.
- The board has approved capital allocation policy for the next 5 years. Effective FY25, the company expects to continue the policy of returning approximately 85% of free cash flows, cumulatively over a 5-year period, through a combination of a semi-annual dividend, share buyback, and special dividend.


Exhibit 1: Infosys - Quarter results (Consol.)

(Rs mn)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	YoY (%)	QoQ (%)	FY23	FY24	YoY (%)
Revenue USD mn	4,554	4,617	4,718	4,663	4,564	0.2	(2.1)	18,212	18,562	1.9
Revenue INR mn	3,74,410	3,79,330	3,89,940	3,88,210	3,79,230	1.3	(2.3)	14,67,670	15,36,710	4.7
Employee costs	2,03,110	2,07,810	2,07,960	2,06,510	2,03,930	0.4	(1.2)	7,83,590	8,26,210	5.4
Subcontractor costs	31,160	31,240	30,740	30,660	29,670	(4.8)	(3.2)	1,40,590	1,22,310	(13.0)
Travel costs	4,260	4,620	4,390	3,870	4,710	10.6	21.7	15,250	17,590	15.3
Other expenses	45,900	45,020	52,450	55,800	53,080	15.6	(4.9)	1,76,940	2,06,350	16.6
EBITDA	89,980	90,640	94,400	91,370	87,840	(2.4)	(3.9)	3,51,300	3,64,250	3.7
Depreciation	11,210	11,730	11,660	11,760	11,630	3.7	(1.1)	42,250	46,780	10.7
EBIT	78,770	78,910	82,740	79,610	76,210	(3.2)	(4.3)	3,09,050	3,17,470	2.7
Finance costs	820	900	1,380	1,310	1,100	34.1	(16.0)	2,840	4,690	65.1
Other income	6,710	5,610	6,320	7,890	27,290	306.7	245.9	27,010	47,110	74.4
PBT	84,660	83,620	87,680	86,190	1,02,400	21.0	18.8	3,33,220	3,59,890	8.0
Tax	23,320	24,170	25,530	25,060	22,650	(2.9)	(9.6)	92,140	97,410	5.7
PAT	61,340	59,450	62,150	61,130	79,750	30.0	30.5	2,41,080	2,62,480	8.9
Share of JVs	(60)	-	(30)	(70)	(60)	-	(14.3)	(130)	(150)	15.4
PAT after JV share	61,280	59,450	62,120	61,060	79,690	30.0	30.5	2,40,950	2,62,330	8.9
EPS (Rs)	14.8	14.4	15.0	14.7	19.2	29.9	30.4	57.6	63.3	9.9
As a % of Revenue						YoY (bps)	QoQ (bps)			YoY (bps)
Employee costs	54.2	54.8	53.3	53.2	53.8	(47)	58	53.4	53.8	37
Subcontractor costs	8.3	8.2	7.9	7.9	7.8	(50)	(7)	9.6	8.0	(162)
Travel costs	1.1	1.2	1.1	1.0	1.2	10	25	1.0	1.1	11
Other expenses	12.3	11.9	13.5	14.4	14.0	174	(38)	12.1	13.4	137
EBITDA margin	24.0	23.9	24.2	23.5	23.2	(87)	(37)	23.9	23.7	(23)
Depreciation	3.0	3.1	3.0	3.0	3.1	7	4	2.9	3.0	17
EBIT margin	21.0	20.8	21.2	20.5	20.1	(94)	(41)	21.1	20.7	(40)
Finance costs	0.2	0.2	0.4	0.3	0.3	7	(5)	0.2	0.3	11
Other income	1.8	1.5	1.6	2.0	7.2	540	516	1.8	3.1	123
PBT	22.6	22.0	22.5	22.2	27.0	439	480	22.7	23.4	72
Effective Tax Rate	27.5	28.9	29.1	29.1	22.1	(543)	(696)	27.7	27.1	(58)
PAT	16.4	15.7	15.9	15.7	21.0	465	529	16.4	17.1	65

Source: Company, Systematix Institutional Research

Exhibit 2: CC YoY revenue growth (%)

Source: Company, Systematix Institutional Research

Exhibit 3: CC QoQ revenue growth (%)


Source: Company, Systematix Institutional Research

Exhibit 4: USD revenue trend


Source: Company, Systematix Institutional Research

Exhibit 5: USD YoY growth


Source: Company, Systematix Institutional Research

Exhibit 6: North America - Revenue trend


Source: Company, Systematix Institutional Research

Exhibit 7: Europe – Revenue trend


Source: Company, Systematix Institutional Research

Exhibit 8: BFSI - Revenue trend


Source: Company, Systematix Institutional Research

Exhibit 9: Retail - Revenue trend


Source: Company, Systematix Institutional Research

Exhibit 10: Manufacturing - Revenue trend

Source: Company, Systematix Institutional Research

Exhibit 11: Communication – Revenue trend

Source: Company, Systematix Institutional Research

Exhibit 12: Energy & Utilities - Revenue trend

Source: Company, Systematix Institutional Research

Exhibit 13: Employee net addition trend

Source: Company, Systematix Institutional Research

Exhibit 14: LTM (Last twelve months) attrition trend




Exhibit 15: Employee cost as a % of sales




Exhibit 16: Subcontractor cost as a % of sales




Exhibit 17: Travel cost as a % of sales



Exhibit 18: EBIT margin trend




Exhibit 19: Large deal TCV trend






Exhibit 20: Client addition trend

Source: Company, Systematix Institutional Research

Exhibit 21: Client addition trend

Source: Company, Systematix Institutional Research

Valuation**Exhibit 22: 1-year forward P/E**

Source: Company, Systematix Institutional Research

Exhibit 23: Change in Estimates

(Rs mn)	Old estimates		New estimates		Variance (%)	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Total Income	16,45,359	18,14,936	15,99,112	17,27,418	(2.8)	(4.8)
EBIT	3,54,179	3,99,994	3,25,428	3,54,108	(8.1)	(11.5)
EBIT margin (%)	21.5	22.0	20.4	20.5	-118 bps	-154 bps
PAT	2,83,735	3,19,091	2,52,543	2,75,161	(11.0)	(13.8)
EPS (Rs)	68.5	77.1	61.0	66.4	(11.0)	(13.8)

Source: Systematix Institutional Research

FINANCIALS

Profit & Loss Statement

YE: Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	12,16,410	14,67,670	15,36,710	15,99,112	17,27,418
Employee benefit exp.	6,39,860	7,83,590	8,26,210	8,59,065	9,26,607
Other expenses	2,61,640	3,32,780	3,46,250	3,67,589	3,99,353
EBITDA	3,14,910	3,51,300	3,64,250	3,72,458	4,01,457
EBITDA margin	25.9%	23.9%	23.7%	23.3%	23.2%
Depreciation	34,760	42,250	46,780	47,030	47,349
EBIT	2,80,150	3,09,050	3,17,470	3,25,428	3,54,108
EBIT margin (%)	23.0	21.1	20.7	20.4	20.5
Interest expense	2,000	2,840	4,690	4,400	4,400
Other income	22,950	27,010	47,110	33,170	35,904
Profit before tax	3,01,100	3,33,220	3,59,890	3,54,198	3,85,612
Taxes	79,640	92,140	97,410	1,01,655	1,10,451
PAT	2,21,100	2,40,950	2,62,330	2,52,543	2,75,161
EPS	52.5	57.6	63.3	61.0	66.4

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Share capital	20,980	20,690	20,710	20,710	20,710
Reserves & Surplus (Ex OCI)	7,32,520	7,33,380	8,60,450	9,14,177	9,90,521
Net worth	7,53,500	7,54,070	8,81,160	9,34,887	10,11,231
Deferred Tax Liability	11,560	12,200	17,940	20,420	22,900
Minority Interest	3,860	3,880	3,450	3,450	3,450
Trade payables	41,340	38,650	39,560	41,166	44,469
Other Provisions	10,670	13,900	18,850	18,860	18,870
Other liabilities	3,57,920	4,35,460	4,17,180	4,18,180	4,19,180
Total Liabilities	11,78,850	12,58,160	13,78,140	14,36,963	15,20,101
Net block	2,63,040	2,96,720	2,80,700	2,83,670	2,86,321
Other Non-current asset	1,07,450	1,26,940	86,040	86,240	86,440
Investments	2,03,240	1,94,780	2,46,230	2,49,730	2,53,230
Cash and Cash Equivalents	1,74,720	1,21,730	1,47,860	1,87,762	2,39,350
Debtors	2,26,980	2,54,240	3,01,930	3,14,191	3,39,400
Other current asset	2,03,420	2,63,750	3,15,380	3,15,370	3,15,360
Total Assets	11,78,850	12,58,160	13,78,140	14,36,963	15,20,101

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
PBT	3,01,100	3,33,220	3,59,890	3,54,198	3,85,612
Depreciation	34,760	42,250	46,780	47,030	47,349
Interest	2,000	2,840	4,690	4,400	4,400
Other Income					
(incl. interest recvd)	-16,450	-18,170	-20,670	-33,170	-35,904
Operating Profit before					
WC Changes	3,37,590	3,83,190	3,95,230	3,72,458	4,01,457
Incr./(decr.) in WC	11,830	65,030	50,820	9,854	21,106
Others including taxes	76,120	87,940	92,310	99,155	1,07,951
Operating cash-flow	2,49,640	2,30,220	2,52,100	2,63,448	2,72,400
Capex	21,610	25,790	22,010	50,000	50,000
Free cash-flow	2,28,030	2,04,430	2,30,090	2,13,448	2,22,400
Dividend	1,27,310	1,36,530	1,46,920	1,98,816	1,98,816
Fin Investments	59,770	(12,990)	44,660	3,500	3,500
Misc. Items (CFI + CFF)	1,12,850	1,33,300	12,420	(28,770)	(31,504)
Net Δ in cash	(72,420)	(52,990)	26,130	39,902	51,588

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY22	FY23	FY24	FY25E	FY26E
Revenue growth	21.1%	20.7%	4.7%	4.1%	8.0%
EBIT (%)	23.0%	21.1%	20.7%	20.4%	20.5%
RoCE	36.3%	40.2%	38.0%	35.0%	35.5%
RoNW	29.3%	32.0%	29.8%	27.0%	27.2%
EPS (Rs)	53	58	63	61	66
DPS (Rs)	31	34	36	40	40
Debtor days	68	63	72	72	72
P/E (x)	27	25	22	23	21
P/B (x)	8	8	7	6	6
EV/EBITDA (x)	18	16	15	15	14

Source: Company, Systematix Institutional Research

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
Equity Research			
Analysts	Industry Sectors	Desk-Phone	E-mail
Dhananjay Sinha	Co Head of Equities & Head of Research - Strategy & Economics	+91-22-6704 8095	dhananjaysinha@systematixgroup.in
Abhishek Mathur	FMCG	+91-22-6704 8059	abhishekmathur@systematixgroup.in
Ashish Poddar	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8039	ashishpoddar@systematixgroup.in
Himanshu Nayyar	Consumer Staples & Discretionary	+91-22-6704 8079	himanshunayyar@systematixgroup.in
Manjith Nair	Banking, Insurance	+91-22-6704 8065	manjithnair@systematixgroup.in
Pradeep Agrawal	NBFCs & Diversified Financials	+91-22-6704 8024	pradeepagrawal@systematixgroup.in
Pratik Tholiya	Specialty & Agro Chem, Fertilisers, Sugar, Textiles and Select Midcaps	+91-22-6704 8028	pratiktholiya@systematixgroup.in
Sameer Pardikar	IT & ITES	+91-22-6704 8041	sameerpardikar@systematixgroup.in
Santosh Yellapu	Capital Goods	+91-22-6704 8094	santoshyellapu@systematixgroup.in
Sudeep Anand	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8085	sudeepanand@systematixgroup.in
Vishal Manchanda	Pharmaceuticals and Healthcare	+91-22-6704 8064	vishalmanchanda@systematixgroup.in
Chetan Mahadik	Consumer Staples & Discretionary	+91-22-6704 8091	chetanmahadik@systematixgroup.in
Deeksha Bhardwaj	Strategy & Economics	+91-22-6704 8017	deekshabhardwaj@systematixgroup.in
Devanshi Kamdar	IT & ITES	+91-22-6704 8098	devanshikamdar@systematixgroup.in
Hinal Kothari	Metals & Mining	+91-22-6704 8076	hinalkothari@systematixgroup.in
Jennisa Popat	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8066	jennisapopat@systematixgroup.in
Kalash Jain	Midcaps	+91-22-6704 8038	kalashjain@systematixgroup.in
Krishna Zaveri	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8023	krishazaveri@systematixgroup.in
Mahek Shah	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8040	mahekshah@systematixgroup.in
Nirali Chheda	Banking, Insurance	+91-22-6704 8019	niralichheda@systematixgroup.in
Pashmi Chheda	Banking, Insurance	+91-22-6704 8063	pashmichheda@systematixgroup.in
Pravin Mule	NBFCs & Diversified Financials	+91-22-6704 8034	pravinmule@systematixgroup.in
Prathmesh Kamath	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8022	prathmeshkamath@systematixgroup.in
Purvi Mundhra	Macro-Strategy	+91-22-6704 8078	purvimumdhra@systematixgroup.in
Rajesh Mudaliar	Consumer Staples & Discretionary	+91-22-6704 8084	rajeshmudaliar@systematixgroup.in
Ronak Dhruv	NBFCs & Diversified Financials	+91-22-6704 8045	ronakdhruv@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Swati Saboo	Midcaps	+91-22-6704 8043	swatisaboo@systematixgroup.in
Vivek Mane	Pharmaceuticals and Healthcare	+91-22-6704 8046	vivekmane@systematixgroup.in
Yogeeta Rathod	Midcaps	+91-22-6704 8081	yogeetarathod@systematixgroup.in
Equity Sales & Trading			
Name		Desk-Phone	E-mail
Vipul Sanghvi	Co Head of Equities & Head of Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Jignesh Desai	Sales	+91-22-6704 8068	jigneshdesai@systematixgroup.in
Sidharth Agrawal	Sales	+91-22-6704 8090	sidharthagrawal@systematixgroup.in
Shreya Chaudhary	Sales	+91-22-6704 8033	shreyachaudhary@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8003	rahul@systematixgroup.in
Chintan Shah	Sales	+91-22-6704 8061	chintanshah@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Karan Damani	Sales Trading	+91-22-6704 8053	karandamani@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8087	vipulchheda@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Rahul Singh	Dealer	+91-22-6704 8054	rahulsingh@systematixgroup.in
Corporate Access			
Mrunal Pawar	Vice President & Head Corporate Access	+91-22-6704 8088	mrunalpawar@systematixgroup.in
Darsha Hiwrale	Associate Corporate Access	+91-22-6704 8083	darshahiwrale@systematixgroup.in
Production			
Madhu Narayanan	Editor	+91-22-6704 8071	madhunarayanan@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in
Operations			
Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Sameer Pardikar; Devanshi Kamdar**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

I. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

II. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell : grievance@systematixgroup.in

Details of Registration : CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI : ARN - 64917